title: Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.
abstract: Tuberculosis (TB) remains a major public health issue due to the increasing incidence of type 2 diabetes mellitus (T2DM), which exacerbates the clinical course of TB and increases the risk of poor long-term outcomes. The aim of this study was to characterize the pharmacokinetics of rifampin (RIF) and its relationship with biochemical and immunological parameters in patients with TB and T2DM. The biochemical and immunological parameters were assessed on the same day that the pharmacokinetic evaluation of RIF was performed. Factors related to the metabolic syndrome that is characteristic of T2DM patients were not detected in the TB-T2DM group (where predominant malnutrition was present) or in the TB group. Percentages of CD8(+) T lymphocytes and NK cells were diminished in the TB and TB-T2DM patients, who had high tumor necrosis factor alpha (TNF-α) and low interleukin-17 (IL-17) levels compared to healthy volunteers. Delayed RIF absorption was observed in the TB and TB-T2DM patients; absorption was poor and slower in the latter group due to poor glycemic control. RIF clearance was also slower in the diabetic patients, thereby prolonging the mean residence time of RIF. There was a significant association between glycemic control, increased TNF-α serum concentrations, and RIF pharmacokinetics in the TB-T2DM patients. These altered metabolic and immune conditions may be factors to be considered in anti-TB therapy management when TB and T2DM are concurrently present.
authors.affiliation: Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
authors.forename: S E
authors.initials: SE
authors.lastname: Medellín-Garibay
authors.affiliation: Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
authors.forename: N
authors.initials: N
authors.lastname: Cortez-Espinosa
authors.affiliation: Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
authors.forename: R C
authors.initials: RC
authors.lastname: Milán-Segovia
authors.affiliation: Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico.
authors.forename: M
authors.initials: M
authors.lastname: Magaña-Aquino
authors.affiliation: Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
authors.forename: J M
authors.initials: JM
authors.lastname: Vargas-Morales
authors.affiliation: Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
authors.forename: R
authors.initials: R
authors.lastname: González-Amaro
authors.affiliation: Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
authors.forename: D P
authors.initials: DP
authors.lastname: Portales-Pérez
authors.affiliation: Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico srm@uaslp.mx.
authors.forename: S
authors.initials: S
authors.lastname: Romano-Moreno
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D020381:Interleukin-17 / Q000378:metabolism; D007694:Killer Cells, Natural / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000276:immunology / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D020381:Interleukin-17; D014409:Tumor Necrosis Factor-alpha; D012293:Rifampin